By targeting treatment-resistant depression, COMP360 will come into competition with Johnson & Johnson’s Spravato (esketamine ... is able to reorganise its structure, function and connections.

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now. Federal regulators approved Johnson & Johnson’s (NYSE: JNJ) nasal ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato was ...

Could nanotechnology improve exercise performance? Evidence from animal studies Lima, M.R. Moreira, B.J. Bertuzzi, R. Lima-Silva, A.E.